Related Experiment Videos
Endothelin-receptor antagonists in uremic cardiomyopathy
S C Wolf1, F Gaschler, S Brehm
1Medical Clinic III, Institute of Physiology, University of Tübingen, Heidelberg, Germany. 101566.341@compuserve.com
Journal of Cardiovascular Pharmacology
|November 15, 2000
Summary
Endothelin receptor antagonists may protect against cardiac hypertrophy and kidney damage in chronic renal failure. These findings suggest a potential therapeutic strategy for improving outcomes in uremic patients.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Elevated endothelin-1 (ET-1) levels in chronic renal failure correlate with disease severity and increased cardiovascular mortality.
- Severe left ventricular hypertrophy (LVH) significantly impacts survival and morbidity in uremic patients.
Purpose of the Study:
- To evaluate the renoprotective and cardioprotective effects of endothelin receptor antagonists in a rat model of chronic uremia.
Main Methods:
- Subtotal nephrectomy (SNX) was performed on Sprague Dawley rats.
- Rats were treated with either an endothelin-A (ET(A)) receptor antagonist (LU302146) or an unselective ET(A)/ET(B) receptor antagonist (LU302872).
- Proteinuria, heart weight, and left ventricular contractility were assessed.
Main Results:
- SNX significantly increased proteinuria compared to sham-operated rats.
- Both ET receptor antagonists reduced proteinuria.
- The ET(A)/ET(B) antagonist decreased heart weight, and both antagonists prevented the impairment of left ventricular contractility observed in SNX rats.
Conclusions:
- Endothelin receptor antagonists demonstrate a potential therapeutic approach for mitigating cardiac hypertrophy and renal proteinuria in chronic kidney disease.
- Further clinical studies are warranted to determine if these protective effects translate to improved survival and life expectancy in patients with chronic renal failure.